EcoDrugPlus

40s Ribosomal Protein S5

Ensembl ID : ENSCING00000002448
Gene Symbol: LOC100186730
4 Cross references
269 Possible Orthologues:

40s Ribosomal Protein S6-Like

Ensembl ID : ENSCING00000001738
Gene Symbol: LOC100181712
4 Cross references
587 Possible Orthologues:

40s Ribosomal Protein S7

Ensembl ID : ENSCING00000001970
Gene Symbol: LOC100177158
4 Cross references
371 Possible Orthologues:

40s Ribosomal Protein S9

Ensembl ID : ENSCING00000021248
Gene Symbol: LOC100184857
4 Cross references
239 Possible Orthologues:

60s Acidic Ribosomal Protein P0

Ensembl ID : ENSCING00000000723
Gene Symbol: LOC100180640
4 Cross references
406 Possible Orthologues:

60s Ribosomal Protein L10a-Like

Ensembl ID : ENSCING00000000891
Gene Symbol: LOC100181568
4 Cross references
382 Possible Orthologues:

60s Ribosomal Protein L11

Ensembl ID : ENSCING00000003326
Gene Symbol: LOC100177507
4 Cross references
293 Possible Orthologues:

60s Ribosomal Protein L12

Ensembl ID : ENSCING00000012950
Gene Symbol: LOC100184231
4 Cross references
492 Possible Orthologues:

60s Ribosomal Protein L13-Like

Ensembl ID : ENSCING00000002582
Gene Symbol: LOC100184047
4 Cross references
275 Possible Orthologues:

60s Ribosomal Protein L13a

Ensembl ID : ENSCING00000014892
Gene Symbol: LOC101243418
4 Cross references
373 Possible Orthologues:

60s Ribosomal Protein L15-Like

Ensembl ID : ENSCING00000001178
Gene Symbol: LOC100175325
4 Cross references
380 Possible Orthologues:

60s Ribosomal Protein L17-Like

Ensembl ID : ENSCING00000011568
Gene Symbol: LOC100184404
4 Cross references
717 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).